Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$77,190.00-1.30%ETH$2,459.99-0.30%GOLD$4,358.50-2.29%OIL$103.93+8.20%
Smart Investors Daily
BG

NASDAQ · BGMSP

Bio Green Med Solution, Inc.

Healthcare · Medical - Pharmaceuticals

$1.44

Up+$0.00 (+0.00%)

Updated Sep 10, 2026, 9:38 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
6.85M
P/E ratio
0
Dividend yield
8.45%
52-week range
$1.44 – $3.40
Volume
4.22K
Avg. volume
5.91K

Price performance

BGMSP price history

1M range · 0 trading sessions · Daily adjusted prices

BGMSP does not have enough price history for the selected period.

Data unavailable

The requested market data was not found.

Latest BGMSP news

The latest Smart Investors Daily articles mentioning BGMSP.

Stock researchCompany · Overview

BGMSP research

Overview

Company profile and research snapshot.

Company profile

Bio Green Med Solution Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
—
Implied upside
—
Analysts
6
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2025

Bio Green Med Solution Reports Third Quarter Financial Results and Provides Business Update

KUALA LUMPUR, Malaysia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ: BGMS, NASDAQ: BGMSP; "BGMS" or the "Company" (formerly Cyclacel Pharmaceuticals, Inc.)), a diversified company engaged primarily in the provision of fire safety protection and distribution activities, today announced third quarter financial results and provided a business update. Highlights of the third quarter ended September 30, 2025, or in some cases shortly thereafter, include: In July, the Compan

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By